<DOC>
	<DOC>NCT01712490</DOC>
	<brief_summary>This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin [Adriamycin], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin [Adriamycin],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)</brief_summary>
	<brief_title>Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Treatmentnaïve Histologically confirmed classical Hodgkin Lymphoma (HL) Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 Bidimensional measurable disease Nodular lymphocyte predominant Hodgkin lymphoma Cerebral/meningeal disease, including signs and symptoms of progressive multifocal leukoencephalopathy (PML) Pulmonary diffusion capacity &gt; 25% lower than normal predicted value Sensory or motor peripheral neuropathy Known human immunodeficiency virus (HIV) positive Known hepatitis B surface antigenpositive, or known or suspected active hepatitis C infection Please note that there are additional exclusion criteria. The study center will determine if you meet all of the criteria.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>Hodgkins Lymphoma</keyword>
	<keyword>Antibody, Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens, CD-30</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoma, Classical</keyword>
	<keyword>ECHELON-1</keyword>
</DOC>